Entrepreneurship for Cardiovascular Health Opportunities (ECHO) is a 12-month national training program supporting cardiovascular research commercialization through education, mentorship, networking, and funding. Led by a diverse team of experts, ECHO fosters...
Entrepreneurship for Cardiovascular Health Opportunities (ECHO) is a 12-month national training program supporting cardiovascular research commercialization through education, mentorship, networking, and funding. Led by a diverse team of experts, ECHO fosters...
With a mission to support novel approaches to managing and preventing heart failure, the Ted Rogers Centre for Heart Research uses its Innovation Fund to propel emerging research with great potential. In our 2024-25 Innovation Seed Grant competition, the Centre funded...
Entrepreneurship for Cardiovascular Health Opportunities (ECHO) is a 12-month national training program supporting cardiovascular research commercialization through education, mentorship, networking, and funding. Led by a diverse team of experts, ECHO fosters...
Entrepreneurship for Cardiovascular Health Opportunities (ECHO) is a 12-month national training program supporting cardiovascular research commercialization through education, mentorship, networking, and funding. Led by a diverse team of experts, ECHO fosters...
Entrepreneurship for Cardiovascular Health Opportunities (ECHO) is a 12-month national training program supporting cardiovascular research commercialization through education, mentorship, networking, and funding. Led by a diverse team of experts, ECHO fosters...
The planning committee for the 2021 Ted Rogers Centre Heart Failure Symposium is pleased to welcome all clinicians, investigators, trainees and interested parties to join this year’s virtual meeting on Dec. 10-11, 2021. This meeting, which blends clinical innovations with the latest scientific advances, has grown to become Canada’s largest conference on heart failure.
On Friday, December 10th, our research-focused symposium examines congenital heart disease, and how we can take animal models and regenerative medicine approaches to answer the clinical challenges that remain. It also highlights commercialization success stories, and sees how innovators developed an idea and translated it to impact. And it will shine a light on unique new scientific approaches in the emerging field of cardiotoxicity.
On Saturday, December 11th, we will reprise a very popular program for primary care practitioners who manage patients with (or at risk of) heart failure, as well as other front-line health-care professionals. Experts will address a range of topics that include emerging therapies, new standards of care, nurse-led initiatives, wearable technology, comorbidities and caring for specialized populations and complex cases. This program will be submitted for accreditation.